Brief: Addex Therapeutics Starts Phase 2 Clinical Study With Dipraglurant
29/09/2021 06:06
Sept 29 (Reuters) - ADDEX THERAPEUTICS LTD ADXN.S :
* ADDEX THERAPEUTICS INITIATES PHASE 2 CLINICAL STUDY WITH
DIPRAGLURANT IN BLEPHAROSPASM
* DATA FROM STUDY ARE EXPECTED IN Q1 2022
Source text for Eikon: ID:nGNE88mQx5
Further company coverage: ADXN.S
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Addex Therapeutics
See all newsBrief: Addex Spin-Out Neurosterix Completes Phase 1 Clinical Studies Of NTX-253 For Schizophrenia
NASDAQ RESUMED AT 11:29 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:24 AM
Switzerland's Addex Therapeutics Q2 net loss narrows on decline in R&D expenses
Brief: Addex Therapeutics Q2 Operating Income CHF -645 Thousand